409 related articles for article (PubMed ID: 30579366)
1. Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.
Orsini P; Impera L; Parciante E; Cumbo C; Minervini CF; Minervini A; Zagaria A; Anelli L; Coccaro N; Casieri P; Tota G; Brunetti C; Ricco A; Carluccio P; Specchia G; Albano F
Diagn Pathol; 2018 Dec; 13(1):98. PubMed ID: 30579366
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
3. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
[TBL] [Abstract][Full Text] [Related]
4. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements.
Yang AS; Estécio MR; Doshi K; Kondo Y; Tajara EH; Issa JP
Nucleic Acids Res; 2004 Feb; 32(3):e38. PubMed ID: 14973332
[TBL] [Abstract][Full Text] [Related]
5. Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia.
Fabris S; Bollati V; Agnelli L; Morabito F; Motta V; Cutrona G; Matis S; Grazia Recchia A; Gigliotti V; Gentile M; Deliliers GL; Bertazzi PA; Ferrarini M; Neri A; Baccarelli A
Epigenetics; 2011 Feb; 6(2):188-94. PubMed ID: 20930513
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome.
Tran HT; Kim HN; Lee IK; Kim YK; Ahn JS; Yang DH; Lee JJ; Kim HJ
J Korean Med Sci; 2011 Feb; 26(2):207-13. PubMed ID: 21286011
[TBL] [Abstract][Full Text] [Related]
7. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
Sekeres MA
Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360
[TBL] [Abstract][Full Text] [Related]
8. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
[TBL] [Abstract][Full Text] [Related]
9. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
10. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
Schmelz K; Sattler N; Wagner M; Lübbert M; Dörken B; Tamm I
Leukemia; 2005 Jan; 19(1):103-11. PubMed ID: 15510208
[TBL] [Abstract][Full Text] [Related]
11. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
12. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
13. Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia.
Wang LQ; Wong KY; Li ZH; Chim CS
Oncotarget; 2016 Dec; 7(50):82400-82410. PubMed ID: 27689399
[TBL] [Abstract][Full Text] [Related]
14. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
Khan H; Vale C; Bhagat T; Verma A
Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
[TBL] [Abstract][Full Text] [Related]
15. Azacytidine causes complex DNA methylation responses in myeloid leukemia.
Stresemann C; Bokelmann I; Mahlknecht U; Lyko F
Mol Cancer Ther; 2008 Sep; 7(9):2998-3005. PubMed ID: 18790780
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
17. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
18. Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer.
Choi SH; Worswick S; Byun HM; Shear T; Soussa JC; Wolff EM; Douer D; Garcia-Manero G; Liang G; Yang AS
Int J Cancer; 2009 Aug; 125(3):723-9. PubMed ID: 19437537
[TBL] [Abstract][Full Text] [Related]
19. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
[No Abstract] [Full Text] [Related]
20. DNA methyltransferases as targets for cancer therapy.
Ghoshal K; Bai S
Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
